A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：44
|
作者：
Badros, Ashraf Z. [1 ]
Kocoglu, Mehmet H. [1 ]
Ma, Ning [1 ]
Rapoport, Aaron P. [1 ]
Lederer, Emily [1 ]
Philip, Sunita [1 ]
Lesho, Patricia [1 ]
Dell, Cameron [1 ]
Hardy, Nancy M. [1 ]
Yared, Jean [1 ]
Goloubeva, Olga [1 ]
Singh, Zeba [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.506.506
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [2] A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
    Rosenberg, Aaron
    Munoz, Meilen
    Costello, Caitlin
    Brem, Elizabeth
    Reid, Erin
    Maverakis, Emanual
    Kaesberg, Paul
    Lee, Lisa
    Abedi, Mehrdad
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S157 - S158
  • [3] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Duran, M.
    Tombuloglu, M.
    Tobu, M.
    Vural, F.
    Sahin, F.
    Patir, P.
    Uysal, A.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
  • [4] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [5] Efficacy and safety of pomalidomide and dexamethasone (Pd) for Chinese patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, single-arm, phase II study
    Lu, J.
    Fu, W-J.
    Wang, Y-F.
    Zhao, H-G.
    Niu, T.
    Fang, B-J.
    Liao, A-J.
    Bai, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S781 - S782
  • [6] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Dimopoulos, M.
    Terpos, E.
    Boccadoro, M.
    Delimpasi, S.
    Beksac, M.
    Katodritou, E.
    Moreau, P.
    Baldini, L.
    Symeonidis, A.
    Bila, J.
    Oriol, A.
    Mateos, M. -, V
    Orfanidis, I
    Ahmadi, T.
    Ukropec, J.
    Kampfenkel, T.
    Schecter, J.
    Qiu, Y.
    Amin, H.
    Vermeulen, J.
    Carson, R.
    Sonneveld, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
  • [7] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    BLOOD, 2015, 126 (23)
  • [8] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [9] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [10] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2020, 136
12345